All In Biotech

Drug Trial Radar · NCT03436849

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects

Phase 1 Study of ESN364 - Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Japanese Male and Healthy Japanese Pre- and Postmenopausal Female Subjects -

Last checked: Nov 20, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Feb 22, 2018

Primary completion

May 23, 2018

Study completion May 23, 2018

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Feb 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of single and multiple oral doses of ESN364 in healthy Japanese male and pre- and post-menopausal female subjects. This study will also evaluate the pharmacokinetics (PK) of ESN364 and its metabolite, and the pharmacodynamics (PD) of ESN364 after single and multiple oral doses administration in healthy Japanese male and pre- and post-menopausal female subjects.

Conditions

  • Healthy Subjects

Interventions

  • ESN364Drug

    ESN364 will be administered orally.

  • PlaceboDrug

    Placebo will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety assessed by incidence of adverse events (AEs) in Part 1Time frame: Up to Day 12 in Part 1
  2. Safety assessed by incidence of AEs in Part 2Time frame: Up to Day 24 in Part 2
  3. Safety assessed by vital signs: Body temperature in Part 1Time frame: Up to day 12 in Part 1
  4. Safety assessed by vital signs: Body temperature in Part 2Time frame: Up to Day 24 in Part 2
  5. Safety assessed by vital signs: Blood pressure in Part 1Time frame: Up to Day 12 in Part 1
  6. Safety assessed by vital signs: Blood pressure in Part 2Time frame: Up to Day 24 in Part 2
  7. Safety assessed by vital signs: Pulse rate in Part 1Time frame: Up to Day 12 in Part 1
  8. Safety assessed by vital signs: Pulse rate in Part 2Time frame: Up to Day 24 in Part 2
  9. Safety assessed by laboratory test: Hematology in Part 1Time frame: Up to Day 12 in Part 1
  10. Safety assessed by laboratory test: Hematology in Part 2Time frame: Up to Day 24 in Part 2
  11. Safety assessed by laboratory test: Biochemistry in Part 1Time frame: Up to Day 12 in Part 1
  12. Safety assessed by laboratory test: Biochemistry in Part 2Time frame: Up to Day 24 in Part 2
  13. Safety assessed by laboratory test: Urinalysis in Part 1Time frame: Up to Day 12 in Part 1
  14. Safety assessed by laboratory test: Urinalysis in Part 2Time frame: Up to Day 24 in Part 2
  15. Safety assessed by standard 12-lead electrocardiogram (ECG) in Part 1Time frame: Up to Day 12 in Part 1
  16. Safety assessed by standard ECG in Part 2Time frame: Up to Day 24 in Part 2
  17. Safety assessed by ECG parameters: Heart rate in Part 1Time frame: Up to 24 hr after dosing in Part 1
  18. Safety assessed by ECG parameters: Heart rate in Part 2Time frame: Up to 24 hr after dosing on Day 10 in multiple dose (MD) of Part 2
  19. Safety assessed by ECG parameters: QT interval in Part 1Time frame: Up to 24 hr after dosing in Part 1
  20. Safety assessed by ECG parameters: QT interval in Part 2Time frame: Up to 24 hr after dosing on Day 10 in MD of Part 2
  21. Safety assessed by ECG parameters: RR interval in Part 1Time frame: Up to 24 hr after dosing in Part 1
  22. Safety assessed by ECG parameters: RR interval in Part 2Time frame: Up to 24 hr after dosing on Day 10 in MD of Part 2
  23. Safety assessed by ECG parameters: PR interval in Part 1Time frame: Up to 24 hr after dosing in Part 1
  24. Safety assessed by ECG parameters: PR interval in Part 2Time frame: Up to 24 hr after dosing on Day 10 in MD of Part 2
  25. Safety assessed by ECG parameters: QRS interval in Part 1Time frame: Up to 24 hr after dosing in Part 1
  26. Safety assessed by ECG parameters: QRS interval in Part 2Time frame: Up to 24 hr after dosing on Day 10 in MD of Part 2
  27. Safety assessed by ECG parameters: QTc interval corrected by Fridericia method (QTcF) in Part 1Time frame: Up to 24 hr after dosing in Part 1
  28. Safety assessed by ECG parameters: QTcF in Part 2Time frame: Up to 24 hr after dosing on Day 10 in MD of Part 2
  29. Safety assessed by body weight in Part 1Time frame: Up to Day 3 in Part 1
  30. Safety assessed by body weight in Part 2Time frame: Up to Day 15 in Part 2
  31. Safety assessed by menstrual cycle in pre-menopausal femalesTime frame: Up to an average of two weeks after last dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site JP00001

    Fukuoka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.